From Envelope to Encephalopathy: How HIV-1 gp120 Drives Neurocognitive Decline
Viruses · 24.04.2026 · 18 (5) · 495
DOI: 10.3390/v18050495 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 24.04.2026. Verfasst von Maryline Santerre und 4 weiteren Autor:innen. Beteiligte Einrichtung: FELS Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, 3307 North Broad Street, Philadelphia, PA 19140, U…. Hauptthemen laut MEDLINE: HIV Envelope Protein gp120, HIV-1, HIV Infections, AIDS Dementia Complex. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIMH NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Although neurons are not productively infected by HIV-1, the envelope glycoprotein gp120, detectable in cerebrospinal fluid independently of active viral replication, gains intraneuronal access via lipid raft-mediated endocytosis, macropinocytosis, and retrograde axonal transport, contributing to persistent neurobiological dysfunction within the central nervous system. Once internalized, gp120 is associated with neuronal dysfunction involving convergent pathways, including excitotoxic calcium dysregulation, mitochondrial and metabolic failure, and inflammatory and senescence-associated amplification. These pathways converge on suppression of CREB and BDNF signaling, dismantling the transcriptional and neurotrophic programs required for synaptic maintenance and cognitive resilience. Extracellular vesicle-mediated dissemination and microRNA reprogramming extend gp120-associated neurobiological effects beyond sites of receptor engagement, while gut-derived metabolites, particularly quinolinic acid, lower the excitotoxic threshold through synergistic activation of NMDA receptors. Together, these mechanisms define HAND as a network disorder in which gp120 contributes to persistent neurocognitive dysfunction beyond active viral replication, identifying convergent therapeutic nodes where combination strategies targeting excitotoxicity, mitochondrial dysfunction, and neuroinflammation offer the most promising path toward durable neuroprotection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- FELS Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, 3307 North Broad Street, Philadelphia, PA 19140, USA.
- Department of Cell and Molecular Biology, School of Osteopathic Medicine, Rowan University, 2 Medical Center Drive, Stratford, NJ 08084, USA.
- Department of Cancer and Cellular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
- Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
ORCID-Profile: Maryline Santerre, Charles N S Allen, Bassel E Sawaya
Förderung
- NIA NIH HHS
- NIMH NIH HHS
- NINDS NIH HHS
- NIH
Zitieren
APA
Santerre, M., Shrestha, J., Allen, C. N. S., Shcherbik, N., & Sawaya, B. E. (2026). From Envelope to Encephalopathy: How HIV-1 gp120 Drives Neurocognitive Decline. Viruses, 18(5), 495. https://doi.org/10.3390/v18050495
Vancouver
Santerre M, Shrestha J, Allen CNS, Shcherbik N, Sawaya BE. From Envelope to Encephalopathy: How HIV-1 gp120 Drives Neurocognitive Decline. Viruses. 2026;18(5):495. doi:10.3390/v18050495
BibTeX
@article{Santerre2026,
author = {Santerre, Maryline and Shrestha, Jenny and Allen, Charles N S and Shcherbik, Natalia and Sawaya, Bassel E},
title = {From Envelope to Encephalopathy: How HIV-1 gp120 Drives Neurocognitive Decline},
journal = {Viruses},
year = {2026},
volume = {18},
number = {5},
pages = {495},
doi = {10.3390/v18050495}
}
EUVIMED